Skip to content Skip to footer

pipeline

KeyZell works on a new therapeutic target for the treatment of cancer, by repositioning an existing molecule on the market, along with other compounds that enhance its efficiency.

JZ-167 has passed efficacy tests in vitro preclinical, in experimental animal models in vivo and in humans. And without affecting healthy cells, that is, without producing toxicity or undesirable effects..